NEW ORLEANS — Glaucoma patients implanted with a bimatoprost ocular insert showed a clinically relevant reduction in IOP over 6 months, according to a study presented here. “[In patients with ocular hypertension], we found that lowering IOP by 20% will decrease the relevant risk of developing glaucoma by 60% among the subjects in our study, and if we achieve this sort of efficacy level, we can prevent many patients from diurnal loss and developing vision loss,” John D. Brandt, MD, said at the Ophthalmology Innovation Summit preceding the American Society (Read more...)
Author: Healio ophthalmology
VIDEO: New data show long-term patient satisfaction with premium IOLs
NEW ORLEANS — At the Ophthalmology Innovation Summit, John A. Hovanesian, MD, FACS, discusses a study showing high patient satisfaction with multifocal and accommodating IOLs at 5 years postop.
VIDEO: Anterior segment diagnostics combined with treatments improve refractive outcomes
NEW ORLEANS — At the Ophthalmology Innovation Summit, James V. Mazzo, chairman and CEO of AcuFocus, discusses the current state of treatment and innovation in improving refractive outcomes for patients, for example, combining anterior segment diagnostics with treatments.
Roger F. Steinert receives OIS Innovator Award
NEW ORLEANS — Roger F. Steinert, MD, was presented with the 2016 OIS Innovator Award here at the Ophthalmology Innovation Summit preceding the American Society of Cataract and Refractive Surgery meeting. “I think many people know that he has been involved in excimer laser research and femtosecond laser research, but he was also involved in a lot of good research in YAG lasers when we first started to incorporate those into our practice,” Richard L. Lindstrom, MD, said in a video tribute. “You are an innovator, someone that I am (Read more...)
VIDEO: TearScience introduces LipiScan meibomian gland imager
NEW ORLEANS — At the Ophthalmology Innovation Summit, Joe Boorady, president and CEO of TearScience, discusses the introduction of a new HD imager that allows for rapid assessment of meibomian gland dysfunction.
VIDEO: Ocular Therapeutix gives update on pipeline of products
NEW ORLEANS — At the Ophthalmology Innovation Summit, Amar Sawhney, PhD, chairman, CEO and president of Ocular Therapeutix, discusses the company’s therapeutics pipeline and progress in approvals and clinical trials.
VIDEO: Bausch + Lomb announces partnership with IBM to create app
NEW ORLEANS — At the Ophthalmology Innovation Summit, Andrew Chang, general manager and vice president U.S. surgical for Bausch + Lomb, discusses the recently announced partnership with IBM, as well as other innovations taking place at the American Society of Cataract and Refractive Surgery meeting.
VIDEO: Aerie gives update on Roclatan and Rhopressa
NEW ORLEANS — At the Ophthalmology Innovation Summit, Tom Mitro, president and COO of Aerie Pharmaceuticals, discusses the current clinical trial status of Roclatan and Rhopressa.
VIDEO: AcuFocus provides update on Kamra, IC-8 IOL
NEW ORLEANS — At the Ophthalmology Innovation Summit, Nick Tarantino, OD, chief of global clinical research and regulatory affairs officer for AcuFocus, gives an update on the launch of the Kamra corneal inlay and the IC-8 small aperture IOL.
VIDEO: Surgeon discusses new oral conscious sedation formula
NEW ORLEANS — At the Ophthalmology Innovation Summit, John Berdahl, MD, discusses the use of a new orally administered conscious sedation formulation for cataract surgery from Imprimis Pharmaceuticals.
VIDEO: Imprimis introduces two new formulations
NEW ORLEANS — At the Ophthalmology Innovation Summit, Mark Baum, CEO of Imprimis Pharmaceuticals, discusses two new formulations for use in cataract surgery.
VIDEO: Novaliq announces full enrollment in phase 2 trial of dry eye treatment
NEW ORLEANS — At the Ophthalmology Innovation Summit, Bernhard Günther, CEO of Novaliq, gives an update on the company portfolio, including news that it had completed enrollment in a phase 2 study of CyclASol for the treatment of moderate to severe dry eye disease.
ARMOR study shows antibiotic resistance levels remain high
SEATTLE – Preliminary 2015 data from the Antibiotic Resistance Monitoring in Ocular Microorganism study show that high levels of antibiotic resistance continue among Staphylococcus, especially the methicillin-resistant strains, according to a poster presented here at the Association of Research in Vision and Ophthalmology meeting. Christine Sanfilippo, PhD, manager of pharmaceutical medical affairs, Bausch + Lomb, told Primary Care Optometry News, “There’s relatively no change in overall trends from 2014. No change means everyone is using good antibiotic stewardship practices.”
Early response to anti-VEGF therapy for DME may predict 3-year outcome
SEATTLE — Optimal and suboptimal early responses to anti-VEGF therapy tended to predict long-term outcomes in patients treated for diabetic macular edema, according to data presented at the Association for Research in Vision and Ophthalmology meeting.In an interview with Ocular Surgery News, Scott M. Whitcup, MD, discussed results of a post hoc analysis of data from the DRCR.net Protocol I study.
Ab interno canaloplasty reduces IOP, medication use in patients with primary open-angle glaucoma
Ab interno canaloplasty reduced IOP and medication use in patients with primary open-angle glaucoma, according to a press release from Ellex Medical Lasers.Ellex reported results of a case series review on ab interno canaloplasty (ABiC), an update of ab externo canaloplasty performed with the iTrack 250-µm microcatheter. ABiC does not require a tensioning suture to maintain IOP reduction and can be performed alone or in combination with cataract surgery, the release said.
Gene therapy improves VA in eyes treated for choroideremia
An adeno-associated virus vector improved visual function in two of six patients treated for choroideremia, according to a letter published in the New England Journal of Medicine.The letter summarized results of a study conducted at the University of O…
VIDEO: Researchers work to improve vision achieved with retinal prostheses
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Andrew Weitz, MD, of the USC Roski Eye Institute, describes research underway to improve the mechanics of sight restoration with retinal prostheses in patients with advanced retinal disease, starting with new techniques of electrical stimulation of surviving retinal cells.
VIDEO: Connectomics used to aggregate data on effects of low vision on visual pathways
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, James Weiland, MD, of the USC Roski Eye Institute, describes connectomics in low vision, a new area of research that incorporates detailed study of structure and function of the retina and of the brain to determine the effect of low vision and blindness on visual pathways.
VIDEO: LADDER trial underway to compare long-term port delivery of ranibizumab with monthly injections
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Jill Hopkins, MD, medical director at Genentech, describes the company’s LADDER trial, an ongoing phase 2 trial whose purpose is to compare monthly intravitreal injections of ranibizumab in patients with wet age-related macular degeneration with long-term delivery of ranibizumab delivered via the company’s port delivery system.
VIDEO: Clinical trials show similarities between ranibizumab, aflibercept in treating DME
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Marco A. Zarbin, MD, PhD, discusses a review of randomized clinical trials of anti-VEGF agents for treating diabetic macular edema, including RISE, RIDE, VIVID, VISTA, RESTORE, Protocol T and Protocol S. The review found that both aflibercept and ranibizumab were “equally effective” in inducing a two-step regression in diabetic retinopathy, durability of the anti-VEGFs was “almost identical,” and incidence of systemic side effects “was comparable” in all the studies, Zarbin said.